Table 2. Prevalence of suspected NAFLD and ultrasonographically-diagnosed NAFLD stratified by marijuana use status.
Never | Past user | Current user | |||
---|---|---|---|---|---|
Suspected NAFLD using elevated ALT (NHANES 2005–2014) | Light user | Heavy user | P-value | ||
NAFLD (%, 95% CI) | 40.7 ± 0.8 (39.0–42.4) | 38.0 ± 0.8 (36.5–39.6) | 30.5 ± 2.2 (26.3–35.1) | 28.0 ± 2.0 (24.2–32.1) | <0.001 |
Gender | |||||
Men (%) | 37.4 | 36.6 | 27.2 | 25.9 | <0.001 |
Women (%) | 43.3 | 39.6 | 34.8 | 32.4 | 0.002 |
Age | |||||
-40 year (%) | 37.8 | 35.1 | 27.4 | 25.7 | <0.001 |
≥40 year (%) | 43.4 | 40.3 | 36.5 | 32.9 | 0.001 |
Ultrasonography-diagnosed NAFLD (NHANES III) | Current user | P-value | |||
NAFLD (%, 95% CI) | 35.0 ± 1.5 (31.9–38.1) | 29.4 ± 2.1 (31.9–38.1) | 23.2 ± 2.5 (18.2–28.2) | <0.001 | |
Gender | |||||
Men (%) | 38.8 | 30.2 | 21.6 | <0.001 | |
Women (%) | 32.2 | 28.4 | 24.5 | 0.039 | |
Age | |||||
-40 year (%) | 38.8 | 30.2 | 21.6 | <0.001 | |
≥40 year (%) | 32.2 | 28.4 | 24.5 | 0.039 |
Data are expressed as the proportion ± SE. Abbreviation: NAFLD, nonalcoholic fatty liver disease; ALT, alanine aminotransferase; NHANES, National Health and Nutrition Examination Survey; CI, confidence interval